Notícias e Atividades da Transcenta
Presença
Transcenta é uma empresa listada sob o símbolo 6628 (CN).
Executivos
Veja o organograma con seus 16 executivos principais
Biografias mais buscadas da Transcenta
- Xueming Qian, Chief Executive Officer and Chairman of the Board
- Helen Chen, Independent Non-Executive Director
- Jiasong Tang, Independent Non-Executive Director
Criar um alerta
para seguir os movimentos de executivos da Transcenta.
Biotecnologia
Transcenta possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).
Popular M&A news in Biotecnologia
- Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
- BioNTech has announced the acquisition of CureVac (publicado em 12 de junho de 2025).
- SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Transcenta
- Transcenta Strengthens Promise for Osemitamab (TST001) for G/GEJ Cancer with OS Data from First-Line Triple Combo Trial Unveiled at 2025 ASCO Annual Meeting-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Promising Anti-Tumor Activity of Novel FGFR2b Targeting ADC with Site-Specific Conjugated Topo I Inhibitor Payload in Preclinical Tumor Models at AACR 2025-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Presents Osemitamab (TST001) and TST003 Study Results at AACR 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta to Present Two Clinical Trial Progress at ASCO 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients-TRANSCENTA HOLDING - A Gl
- View more press releases Close
Redes sociais sobre Transcenta
- Transcenta na Wikipedia, Google News e Yahoo Finance
- Transcenta na LinkedIn, Twitter e YouTube
